Mylan announced the launch of Paliperidone Extended-Release Tablets, the generic version of Janssen’s Invega.

Invega is indicated for the treatment of schizophrenia in adolescents (12–17 years old) and adults as well as schizoaffective disorder as monotherapy and as an adjunct to mood stabilizers and/or antidepressants in adults. The mechanism of action of paliperidone, as with other drugs having efficacy in schizophrenia, is unknown, but it has been proposed that the drug’s therapeutic activity in schizophrenia is mediated through a combination of D2 and 5HT2A receptor antagonism.

RELATED: Vraylar Gets FDA Approval

Paliperidone Extended-Release Tablets are available in 1.5mg, 3mg, 6mg, and 9mg strengths.

For more information call (800) RX-MYLAN or visit